Advances in translational lung cancer research in 2025: a narrative review
Yuhan Xu, Yanbin Kuang, Yeqin Guo, Yuqing Lou · 2026
Read Advances in translational lung cancer research in 2025: a narrative review by Yuhan Xu, Yanbin Kuang, Yeqin Guo, Yuqing Lou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13263839.txt.
Description
Yuhan Xu and colleagues surveyed in 2026 the year's translational lung cancer research, the work that carries lab findings toward the clinic. They searched two major databases and sorted 2025 findings into five areas. Drug resistance and tumor diversity framed the review as the field's twin obstacles.
Early detection advanced through liquid biopsy methods that also track leftover disease after treatment. Marker work moved from single markers to combined panels that better predict who responds. New drug classes, including antibody-drug conjugates and bispecific antibodies, showed gains across tumor types and stages. Resistance studies now reclassify tumors at failure and rematch therapy to match. Models grown from patient tissue, joined with AI analysis, strengthened the chain from lab to clinic. The authors see a patient-centered precision framework knitting these strands together.
Catalog record
| CREATOR | Yuhan Xu, Yanbin Kuang, Yeqin Guo, Yuqing Lou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |